Treatment options for limited or symptomatic metastatic melanoma

James Mcloughlin, Jonathan S. Zager, Vernon K. Sondak, Lawrence B. Berk

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Background: Patients who develop metastatic melanoma often have limited effective treatment options. However, a select group of patients will benefit from aggressive surgery or a multidisciplinary approach, depending on the site of metastasis. Methods: The current literature was reviewed and summarized regarding the collective recommendations for staging and treating patients with metastatic melanoma. Results: A thorough preoperative staging includes positron-emission tomography, MRI of the brain, and CT of the chest, abdomen, and pelvis. Tumor biology ultimately determines the success of intervention. A long disease-free interval is a good indicator of potential benefit from resection of metastatic disease. If surgery is performed, no less than a complete resection will affect the overall survival of the patient. Surgery and other multimodality treatment options can be used for symptomatic palliation but will not affect survival. Chemotherapy and radiation are often used to control the symptoms of brain and bony metastases but have limited if any impact on survival. Conclusions: A select group of patients with metastatic melanoma will benefit from aggressive surgery. Identifying which patients will benefit from treatment requires good clinical judgment and a thorough radiologic evaluation to identify the true extent of disease.

Original languageEnglish (US)
Pages (from-to)239-247
Number of pages9
JournalCancer Control
Volume15
Issue number3
DOIs
StatePublished - Jan 1 2008

Fingerprint

Melanoma
Survival
Therapeutics
Neoplasm Metastasis
Brain
Pelvis
Positron-Emission Tomography
Abdomen
Thorax
Radiation
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Treatment options for limited or symptomatic metastatic melanoma. / Mcloughlin, James; Zager, Jonathan S.; Sondak, Vernon K.; Berk, Lawrence B.

In: Cancer Control, Vol. 15, No. 3, 01.01.2008, p. 239-247.

Research output: Contribution to journalReview article

Mcloughlin, James ; Zager, Jonathan S. ; Sondak, Vernon K. ; Berk, Lawrence B. / Treatment options for limited or symptomatic metastatic melanoma. In: Cancer Control. 2008 ; Vol. 15, No. 3. pp. 239-247.
@article{be572fdaa80e43fcafd1bb09723ceafd,
title = "Treatment options for limited or symptomatic metastatic melanoma",
abstract = "Background: Patients who develop metastatic melanoma often have limited effective treatment options. However, a select group of patients will benefit from aggressive surgery or a multidisciplinary approach, depending on the site of metastasis. Methods: The current literature was reviewed and summarized regarding the collective recommendations for staging and treating patients with metastatic melanoma. Results: A thorough preoperative staging includes positron-emission tomography, MRI of the brain, and CT of the chest, abdomen, and pelvis. Tumor biology ultimately determines the success of intervention. A long disease-free interval is a good indicator of potential benefit from resection of metastatic disease. If surgery is performed, no less than a complete resection will affect the overall survival of the patient. Surgery and other multimodality treatment options can be used for symptomatic palliation but will not affect survival. Chemotherapy and radiation are often used to control the symptoms of brain and bony metastases but have limited if any impact on survival. Conclusions: A select group of patients with metastatic melanoma will benefit from aggressive surgery. Identifying which patients will benefit from treatment requires good clinical judgment and a thorough radiologic evaluation to identify the true extent of disease.",
author = "James Mcloughlin and Zager, {Jonathan S.} and Sondak, {Vernon K.} and Berk, {Lawrence B.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1177/107327480801500307",
language = "English (US)",
volume = "15",
pages = "239--247",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "3",

}

TY - JOUR

T1 - Treatment options for limited or symptomatic metastatic melanoma

AU - Mcloughlin, James

AU - Zager, Jonathan S.

AU - Sondak, Vernon K.

AU - Berk, Lawrence B.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background: Patients who develop metastatic melanoma often have limited effective treatment options. However, a select group of patients will benefit from aggressive surgery or a multidisciplinary approach, depending on the site of metastasis. Methods: The current literature was reviewed and summarized regarding the collective recommendations for staging and treating patients with metastatic melanoma. Results: A thorough preoperative staging includes positron-emission tomography, MRI of the brain, and CT of the chest, abdomen, and pelvis. Tumor biology ultimately determines the success of intervention. A long disease-free interval is a good indicator of potential benefit from resection of metastatic disease. If surgery is performed, no less than a complete resection will affect the overall survival of the patient. Surgery and other multimodality treatment options can be used for symptomatic palliation but will not affect survival. Chemotherapy and radiation are often used to control the symptoms of brain and bony metastases but have limited if any impact on survival. Conclusions: A select group of patients with metastatic melanoma will benefit from aggressive surgery. Identifying which patients will benefit from treatment requires good clinical judgment and a thorough radiologic evaluation to identify the true extent of disease.

AB - Background: Patients who develop metastatic melanoma often have limited effective treatment options. However, a select group of patients will benefit from aggressive surgery or a multidisciplinary approach, depending on the site of metastasis. Methods: The current literature was reviewed and summarized regarding the collective recommendations for staging and treating patients with metastatic melanoma. Results: A thorough preoperative staging includes positron-emission tomography, MRI of the brain, and CT of the chest, abdomen, and pelvis. Tumor biology ultimately determines the success of intervention. A long disease-free interval is a good indicator of potential benefit from resection of metastatic disease. If surgery is performed, no less than a complete resection will affect the overall survival of the patient. Surgery and other multimodality treatment options can be used for symptomatic palliation but will not affect survival. Chemotherapy and radiation are often used to control the symptoms of brain and bony metastases but have limited if any impact on survival. Conclusions: A select group of patients with metastatic melanoma will benefit from aggressive surgery. Identifying which patients will benefit from treatment requires good clinical judgment and a thorough radiologic evaluation to identify the true extent of disease.

UR - http://www.scopus.com/inward/record.url?scp=49649093753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649093753&partnerID=8YFLogxK

U2 - 10.1177/107327480801500307

DO - 10.1177/107327480801500307

M3 - Review article

VL - 15

SP - 239

EP - 247

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 3

ER -